Novo Nordisk is investing $2 billion US dollars in a new production facility in Clayton, NC. Voted to Carolina Parenting Inc. Magazine’s List of “Top 50 Family Friendly Companies” and Most Valuable Employer for Military® by CivilianJobs.com, the Diabetes Finished Products and Diabetes Active Pharmaceutical Ingredients manufacturing facilities in Clayton, North Carolina will soon employ nearly 1,500 members of the community in Johnston County near the Research Triangle.
Diabetes Finished Products (DFP)
DFP helps support Novo Nordisk as a leader in diabetes by providing a complete product portfolio of insulin and GLP-1 products and offers easy-to-use insulin delivery systems. DFP is the primary supplier of Novo Nordisk diabetes and obesity products for the US market and secondary supplier in certain other foreign markets.
Diabetes Active Pharmaceutical Ingredients (DAPI)
To help meet the growing demand for our diabetes treatment, Novo Nordisk expects to double production of diabetes drugs over the next decade. Novo Nordisk is currently building a new diabetes API plant in Clayton, NC. The new plant will initially employ 700 employees to produce the active ingredients for new and current GLP-1 for diabetes and obesity products, as well as intermediates for already marketed insulins.
In the Community
Outside of excellence in manufacturing, Novo Nordisk supports the Clayton community through a variety of projects, including sponsorship of JDRF and the American Diabetes Association chapters and participation in local projects with Backpack Buddies, United Way and Angel Tree.